Nelfinavir (Viracept) approved: fourth protease inhibitor available
- PMID: 11364249
Nelfinavir (Viracept) approved: fourth protease inhibitor available
Abstract
AIDS: The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV infection when antiretroviral therapy is warranted. The drug is the fourth protease inhibitor to gain FDA approval. The recommended dose for adults is 750 mg three times daily, taken with food. The package insert warns of several potential drug interactions, and cautions that the most usual side effect is diarrhea. Developer Agouron Pharmaceuticals has established patient assistance programs to help patients pay for the medication, and are making the drug available through government discount programs.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical